Breaking Finance News

Trevana (NASDAQ:TRVN) price target dropped to $7.00, released a report earlier today by H.C. Wainwright

H.C. Wainwright bumped down the target of Trevana (NASDAQ:TRVN) to $7.00 stating a potential upside of 1.95%.

Showing a price of $2.37, Trevana (NASDAQ:TRVN) traded -3.27% lower on the day. The last stock close price is down -13.88% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the date range. Trevana has recorded a 50-day average of $2.49 and a two hundred day average of $2.75. Trade Volume was up over the average, with 1,485,513 shares of TRVN changing hands over the typical 497,832

Performance Chart

Trevana (NASDAQ:TRVN)

Trevana has a 52 week low of $2.15 and a 52 week high of $8.00 The company’s market cap is currently $0.

In addition to H.C. Wainwright reporting its stock price target, a total of 10 brokers have issued a research note on the company. The average stock price target is $14.55 with 4 brokerages rating the stock a strong buy, 6 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Trevana (NASDAQ:TRVN)

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *